Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Acute HIT II (Heparin-induced Thrombocytopenia Type II)

Treatments: Drug: argatroban; Drug: danaparoid; Drug: fondaparinux; Drug: lepirudin

Study type: Observational

Funder types: Industry

Identifiers

NCT01304238

108745

Details and patient eligibility

About

The purpose of this retrospective registry is to collect data about patients with acute HIT II (Heparin-induced Thrombocytopenia type II) which were treated with Lepirudin, Danaparoid, Argatroban or Fondaparinux. It is a main objective of this registry to mirror the daily routine in this indication in Germany.

Enrollment: 195 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Acute HIT II (Heparin-induced Thrombocytopenia type II), 4T-Score
• Treatment of HIT with Lepirudin, Danaparoid, Argatroban or Fondaparinux

Exclusion criteria

Trial design

195 participants in 4 patient groups

lepirudin

Description:

lepirudin treated subjects

Treatment:

Drug: lepirudin

danaparoid

Description:

danaparoid treated subjects

Treatment:

Drug: danaparoid

argatroban

Description:

argatroban treated subjects

Treatment:

Drug: argatroban

fondaparinux

Description:

fondaparinux treated subjects

Treatment:

Drug: fondaparinux